跳至主要内容

Cholangiocarcinoma in Patients with Crohn’s Disease

Read full paper at:
http://www.scirp.org/journal/PaperInformation.aspx?PaperID=52687#.VKC_4cCAM4

Cholangiocarcinoma is an uncommon malignancy that increases with age. Cholangiocarcinoma has been linked to inflammatory bowel disease, and a relationship between inflammatory bowel disease, anti-tumour necrosis factor alpha antibody (Infliximab) and cholangiocarcinoma has been suggested. Although cholangiocarcinoma is usually associated with ulcerative colitis, recently more cases are being seen in association with Crohn’s disease. The risk of cancer in patients treated with Infliximab has been discussed, and whether Infliximab is associated with an increased risk of cholangiocarcinoma is not clear. Cholangiocarcinoma is an uncommon malignancy and it is difficult to establish a clear correlation with Infliximab treatment. A large number of reports are needed to further address these issues. 
Cite this paper
Debs, T. , Reccia, I. , El-Hajj, I. and El-Rassi, Z. (2015) Cholangiocarcinoma in Patients with Crohn’s Disease. Journal of Cancer Therapy, 6, 21-24. doi: 10.4236/jct.2015.61003. 
 

[1] Bragazzi, M.C., Cardinale, V., Carpino, G., Venere, R., Semeraro, R., Gentile, R., Gaudio, E. and Alvaro, D. (2012) Cholangiocarcinoma: Epidemiology and Risk Factors. Translational Gastrointestinal Cancer, 1, 21-32.
[2] Blechacz, B., Komuta, M., Roskams, T., Gores, G.J., et al. (2011) Clinical Diagnosis and Staging of Cholangiocarcinoma. Nature Reviews Gastroenterology & Hepatology, 8, 512-522.
http://dx.doi.org/10.1038/nrgastro.2011.131
[3] Patel, T. (2011) Cholangiocarcinoma—Controversies and Challenges. Nature Reviews Gastroenterology & Hepatology, 8, 189-200. http://dx.doi.org/10.1038/nrgastro.2011.20
[4] Carriaga, M.T. and Henson, D.E. (1995) Liver, Gallbladder, Extrahepatic Bile Ducts, and Pancreas. Cancer, 75, 171-190.
http://dx.doi.org/10.1002/1097-0142(19950101)75:1+<171::AID-CNCR2820751306>3.0.CO;2-2
[5] Shaib, Y.H. and El-Serag, H.B. (2004) The Epidemiology of Cholangiocarcinoma. Seminars in Liver Disease, 24, 115-125. http://dx.doi.org/10.1055/s-2004-828889
[6] Schnitzler, F., Fidder, H., Ferrante, M., Noman, M., Arijs, I., Van Assche, G., Hoffman, I., Van Steen, K., Vermeire, S. and Rutgeerts, P. (2009) Long-Term Outcome of Treatment with Infliximab in 614 Patients with Crohn’s Disease: Results from a Single-Centre Cohort. Gut, 58, 492-500.
http://dx.doi.org/10.1136/gut.2008.155812
[7] O’Donnell, S., Murphy, S., Anwar, M.M., O’Sullivan, M., Breslin, N., O’Connor, H.J., Ryan, B.M. and O’Morain, C.A. (2011) Safety of Infliximab in 10 Years of Clinical Practice. European Journal of Gastroenterology & Hepatology, 23, 603-606. http://dx.doi.org/10.1097/MEG.0b013e3283479125
[8] Hudesman, D., Lichtiger, S. and Sands, B. (2013) Risk of Extraintestinal Solid Cancer with Anti-TNF Therapy in Adults with Inflammatory Bowel Disease: Review of the Literature. Inflammatory Bowel Diseases, 19, 644-649. http://dx.doi.org/10.1097/MIB.0b013e318280ebbd
[9] Lust, M. and Travis, S. (2009) Is Anti-TNF Therapy Always Prohibited in Patients with Inflammatory Bowel Disease and Previous Malignancy? Practical Gastroenterology. Inflammatory Bowel Disease.
[10] Rojas-Feria, M., Castro, M., Suárez, E., Ampuero, J. and Romero-Gómez, M. (2013) Hepatobiliary Manifestations in Inflammatory Bowel Disease: The Gut, the Drugs and the Liver. World Journal of Gastroenterology, 19, 7327-7340. http://dx.doi.org/10.3748/wjg.v19.i42.7327
[11] Pedersen, N., Duricova, D., Elkjaer, M., Gamborg, M., Munkholm, P. and Jess, T. (2010) Risk of Extra-Intestinal Cancer in Inflammatory Bowel Disease: Meta-Analysis of Population-Based Cohort Studies. American Journal of Gastroenterology, 105, 1480-1487. http://dx.doi.org/10.1038/ajg.2009.760
[12] Erichsen, R., Jepsen, P., Vilstrup, H., Ekbom, A. and S?rensen, H.T. (2009) Incidence and Prognosis of Cholangiocarcinoma in Danish Patients with and without Inflammatory Bowel Disease: A National Cohort Study, 1978-2003. European Journal of Epidemiology, 24, 513-520. http://dx.doi.org/10.1007/s10654-009-9365-4
[13] Biancone, L., Orlando, A., Kohn, A., Colombo, E., Sostegni, R., Angelucci, E., Rizzello, F., Castiglione, F., Benazzato, L., Papi, C., Meucci, G., Riegler, G., Petruzziello, C., Mocciaro, F., Geremia, A., Calabrese, E., Cottone, M. and Pallone, F. (2006) Infliximab and Newly Diagnosed Neoplasia in Crohn’s Disease: A Multicentre Matched Pair Study. Gut, 55, 228-233. http://dx.doi.org/10.1136/gut.2005.075937
[14] Berman, M.D., Falchuk, K.R. and Trey, C. (1980) Carcinoma of the Biliary Tree Complicating Crohn’s Disease. Digestive Diseases and Sciences, 25, 795-797. http://dx.doi.org/10.1007/BF01345302
[15] Krause, J.R., Ayuyang, H.Q. and Ellis, L.D. (1985) Occurrence of Three Cases of Carcinoma in Individuals with Crohn’s Disease Treated with Metronidazole. American Journal of Gastroenterology, 80, 978-982.
[16] Altaee, M.Y., Johnson, P.J., Farrant, J.M. and Williams, R. (1991) Etiologic and Clinical Characteristics of Peripheral and Hilar Cholangiocarcinoma. Cancer, 68, 2051-2055. http://dx.doi.org/10.1002/1097-0142(19911101)68:9<2051::AID-CNCR2820680934>3.0.CO;2-M
[17] Choi, P.M., Nugent, F.W., Zelig, M.P., Munson, J.L. and Schoetz Jr., D.J. (1994) Cholangiocarcinoma and Crohn’s Disease. Digestive Diseases and Sciences, 39, 667-670. http://dx.doi.org/10.1007/BF02088359
[18] Bragazzi, M.C., Cardinale, V., Carpino, G., Venere, R., Semeraro, R., Gentile, R., Gaudio, E. and Alvaro, D. (2012) Cholangiocarcinoma: Epidemiology and Risk Factors. Translational Gastrointestinal Cancer, 1, 21-32.
[19] Blechacz, B., Komuta, M., Roskams, T., Gores, G.J., et al. (2011) Clinical Diagnosis and Staging of Cholangiocarcinoma. Nature Reviews Gastroenterology & Hepatology, 8, 512-522.
http://dx.doi.org/10.1038/nrgastro.2011.131
[20] Patel, T. (2011) Cholangiocarcinoma—Controversies and Challenges. Nature Reviews Gastroenterology & Hepatology, 8, 189-200. http://dx.doi.org/10.1038/nrgastro.2011.20
[21] Carriaga, M.T. and Henson, D.E. (1995) Liver, Gallbladder, Extrahepatic Bile Ducts, and Pancreas. Cancer, 75, 171-190.
http://dx.doi.org/10.1002/1097-0142(19950101)75:1+<171::AID-CNCR2820751306>3.0.CO;2-2
[22] Shaib, Y.H. and El-Serag, H.B. (2004) The Epidemiology of Cholangiocarcinoma. Seminars in Liver Disease, 24, 115-125. http://dx.doi.org/10.1055/s-2004-828889
[23] Schnitzler, F., Fidder, H., Ferrante, M., Noman, M., Arijs, I., Van Assche, G., Hoffman, I., Van Steen, K., Vermeire, S. and Rutgeerts, P. (2009) Long-Term Outcome of Treatment with Infliximab in 614 Patients with Crohn’s Disease: Results from a Single-Centre Cohort. Gut, 58, 492-500.
http://dx.doi.org/10.1136/gut.2008.155812
[24] O’Donnell, S., Murphy, S., Anwar, M.M., O’Sullivan, M., Breslin, N., O’Connor, H.J., Ryan, B.M. and O’Morain, C.A. (2011) Safety of Infliximab in 10 Years of Clinical Practice. European Journal of Gastroenterology & Hepatology, 23, 603-606. http://dx.doi.org/10.1097/MEG.0b013e3283479125
[25] Hudesman, D., Lichtiger, S. and Sands, B. (2013) Risk of Extraintestinal Solid Cancer with Anti-TNF Therapy in Adults with Inflammatory Bowel Disease: Review of the Literature. Inflammatory Bowel Diseases, 19, 644-649. http://dx.doi.org/10.1097/MIB.0b013e318280ebbd
[26] Lust, M. and Travis, S. (2009) Is Anti-TNF Therapy Always Prohibited in Patients with Inflammatory Bowel Disease and Previous Malignancy? Practical Gastroenterology. Inflammatory Bowel Disease.
[27] Rojas-Feria, M., Castro, M., Suárez, E., Ampuero, J. and Romero-Gómez, M. (2013) Hepatobiliary Manifestations in Inflammatory Bowel Disease: The Gut, the Drugs and the Liver. World Journal of Gastroenterology, 19, 7327-7340. http://dx.doi.org/10.3748/wjg.v19.i42.7327
[28] Pedersen, N., Duricova, D., Elkjaer, M., Gamborg, M., Munkholm, P. and Jess, T. (2010) Risk of Extra-Intestinal Cancer in Inflammatory Bowel Disease: Meta-Analysis of Population-Based Cohort Studies. American Journal of Gastroenterology, 105, 1480-1487. http://dx.doi.org/10.1038/ajg.2009.760
[29] Erichsen, R., Jepsen, P., Vilstrup, H., Ekbom, A. and S?rensen, H.T. (2009) Incidence and Prognosis of Cholangiocarcinoma in Danish Patients with and without Inflammatory Bowel Disease: A National Cohort Study, 1978-2003. European Journal of Epidemiology, 24, 513-520. http://dx.doi.org/10.1007/s10654-009-9365-4
[30] Biancone, L., Orlando, A., Kohn, A., Colombo, E., Sostegni, R., Angelucci, E., Rizzello, F., Castiglione, F., Benazzato, L., Papi, C., Meucci, G., Riegler, G., Petruzziello, C., Mocciaro, F., Geremia, A., Calabrese, E., Cottone, M. and Pallone, F. (2006) Infliximab and Newly Diagnosed Neoplasia in Crohn’s Disease: A Multicentre Matched Pair Study. Gut, 55, 228-233. http://dx.doi.org/10.1136/gut.2005.075937
[31] Berman, M.D., Falchuk, K.R. and Trey, C. (1980) Carcinoma of the Biliary Tree Complicating Crohn’s Disease. Digestive Diseases and Sciences, 25, 795-797. http://dx.doi.org/10.1007/BF01345302
[32] Krause, J.R., Ayuyang, H.Q. and Ellis, L.D. (1985) Occurrence of Three Cases of Carcinoma in Individuals with Crohn’s Disease Treated with Metronidazole. American Journal of Gastroenterology, 80, 978-982.
[33] Altaee, M.Y., Johnson, P.J., Farrant, J.M. and Williams, R. (1991) Etiologic and Clinical Characteristics of Peripheral and Hilar Cholangiocarcinoma. Cancer, 68, 2051-2055. http://dx.doi.org/10.1002/1097-0142(19911101)68:9<2051::AID-CNCR2820680934>3.0.CO;2-M
[34] Choi, P.M., Nugent, F.W., Zelig, M.P., Munson, J.L. and Schoetz Jr., D.J. (1994) Cholangiocarcinoma and Crohn’s Disease. Digestive Diseases and Sciences, 39, 667-670. http://dx.doi.org/10.1007/BF02088359  eww141229lx
标签：

评论

发表评论

此博客中的热门博文

A Comparison of Methods Used to Determine the Oleic/Linoleic Acid Ratio in Cultivated Peanut (Arachis hypogaea L.)

Cultivated peanut ( Arachis hypogaea L.) is an important oil and food crop. It is also a cheap source of protein, a good source of essential vitamins and minerals, and a component of many food products. The fatty acid composition of peanuts has become increasingly important with the realization that oleic acid content significantly affects the development of rancidity. And oil content of peanuts significantly affects flavor and shelf-life. Early generation screening of breeding lines for high oleic acid content greatly increases the efficiency of developing new peanut varieties. The objective of this study was to compare the accuracy of methods used to classify individual peanut seed as high oleic or not high oleic. Three hundred and seventy-four (374) seeds, spanning twenty-three (23) genotypes varying in oil composition (i.e. high oleic (H) or normal/not high oleic (NH) inclusive of all four peanut market-types (runner, Spanish, Valencia and Virginia), were individually tested ...
发表评论
阅读全文

Location Optimization of a Coal Power Plant to Balance Costs against Plant’s Emission Exposure

Fuel and its delivery cost comprise the biggest expense in coal power plant operations. Delivery of electricity from generation to consumers requires investment in power lines and transmission grids. Placing a coal power plant or multiple power plants near dense population centers can lower transmission costs. If a coalmine is nearby, transportation costs can also be reduced. However, emissions from coal plants play a key role in worsening health crises in many countries. And coal upon combustion produces CO 2 , SO 2 , NO x , CO, Metallic and Particle Matter (PM10 & PM2.5). The presence of these chemical compounds in the atmosphere in close vicinity to humans, livestock, and agriculture carries detrimental health consequences. The goal of the research was to develop a methodology to minimize the public’s exposure to harmful emissions from coal power plants while maintaining minimal operational costs related to electric distribution losses and coal logistics. The objective was...
发表评论
阅读全文

Evaluation of the Safety and Efficacy of Continuous Use of a Home-Use High-Frequency Facial Treatment Appliance

At present, many home-use beauty devices are available in the market. In particular, many products developed for facial treatment use light, e.g., a flash lamp or a light-emitting diode (LED). In this study, the safety of 4 weeks’ continuous use of NEWA TM , a high-frequency facial treatment appliance, every alternate day at home was verified, and its efficacy was evaluated in Japanese individuals with healthy skin aged 30 years or older who complained of sagging of the facial skin.  Transepidermal water loss (TEWL), melanin levels, erythema levels, sebum secretion levels, skin color changes and wrinkle improvement in the facial skin were measured before the appliance began to be used (study baseline), at 2 and 4 weeks after it had begun to be used, and at 2 weeks after completion of the 4-week treatment period (6 weeks from the study baseline). In addition, data obtained by subjective evaluation by the subjects themselves on a visual analog scale (VAS) were also analyzed. Fur...
发表评论
阅读全文